Results 101 to 110 of about 414,372 (151)

Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes. [PDF]

Diabetes Care, 2023
Svehlikova E, Ashcroft NL, Gatschelhofer C, Gerring D, Höller V, Jezek J, Lackner B, Lawrence F, Pillai V, Ratzer M, Urschitz M, Wolf M, Pieber TR.   +12 more
europepmc   +1 more source

Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery. [PDF]

Diabetes Obes Metab
Dovč K, Spanbauer C, Chiarle E, Bratina N, Fröhlich-Reiterer E, Potočnik N, Zaharieva DP, Hropot T, Fritsch M, Calhoun P, Battelino T.   +10 more
europepmc   +1 more source

Sensor-derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster acting insulin aspart or insulin aspart-A secondary analysis of the CopenFast trial. [PDF]

Diabet Med
Søholm JC, Nørgaard SK, Nørgaard K, Clausen TD, Damm P, Mathiesen ER, Ringholm L.   +6 more
europepmc   +1 more source

Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy. [PDF]

Indian J Endocrinol Metab, 2022
Mohan V, Schmider W, Singh KP, Rotthaeuser B, Mukherjee B, Aravind SR.   +5 more
europepmc   +1 more source

Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial. [PDF]

J Diabetes Sci Technol
Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, Kramer D, Schmider W, Pierre S, Teichert L, Rotthaeuser B, Mukherjee B, Bailey TS.   +12 more
europepmc   +1 more source

Comparison of the effectiveness of fast-acting insulin aspart with rapid-acting insulin analogues on glycaemic control: a retrospective cohort study using patient data from primary care practices in England. [PDF]

BMJ Open
Davies MJ, Alibegovic AC, Jensen AB, Kelkar P, Nordsborg RB, Thamattoor UK, Braae UC.   +6 more
europepmc   +1 more source

Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M). [PDF]

Diabetes Ther, 2022
Aravind SR, Singh KP, Aquitania G, Mogylnytska L, Zalevskaya AG, Matyjaszek-Matuszek B, Wernicke-Panten K, Nguyên-Pascal ML, Pierre S, Rotthaeuser B, Kramer D, Mukherjee B.   +11 more
europepmc   +1 more source

Effects of metformin combined with insulin aspart on gestational weight gain, lipid metabolism, immune function, and delivery outcomes in pregnant women with gestational diabetes. [PDF]

Am J Transl Res
Cui J, Huang Y, Wang X.
europepmc   +1 more source

A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. [PDF]

Diabetes Technol Ther, 2022
Beck RW, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Li Z, Calhoun P.   +7 more
europepmc   +1 more source

Subcutaneous Insulin Aspart Every 4 Hours in the Treatment of COVID-19 Patients With Mild-to-Moderate Diabetic Ketoacidosis: A Case Series. [PDF]

J Community Hosp Intern Med Perspect
Chiewchalermsri D, Wanittansirichok C, Sriphrapradang C.   +2 more
europepmc   +1 more source